Greenwich LifeSciences, Inc. (GLSI) Balance Sheet

The transition from a positive cash position to a deficit suggests that the company has exhausted its internal reserves, leaving it highly exposed to market volatility. Investors should monitor the company's ability to secure non-dilutive funding or equity financing, as the current liquidity profile appears insufficient to support long-term clinical operations.

This downward trend in total assets indicates that the firm is rapidly depleting its financial resources, which may necessitate immediate and potentially dilutive capital raises. The lack of asset growth suggests that the business model remains entirely dependent on external financing rather than internal value creation.

The consistent decline in equity highlights the structural challenge of funding high-cost clinical trials through equity issuance. This erosion warrants further investigation into the potential for future share dilution, as the company must continue to fund its operations while maintaining a viable capital structure for potential investors.